Puma Biotechnology Inc (PBYI) Financial Statements (2026 and earlier)

Company Profile

Business Address 10880 WILSHIRE BLVD.
LOS ANGELES, CA 90024
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:91,62788,42588,74182,12186,83889,907
Cash and cash equivalent29,63553,52554,66263,03069,21967,263
Short-term investments67,89340,86341,36230,13731,74629,462
Other undisclosed cash, cash equivalents, and short-term investments(5,901)(5,963)(7,283)(11,046)(14,127)(6,818)
Restricted cash and investments2,0912,0912,091   
Receivables53,65433,56525,91025,17232,01154,643
Inventory, net of allowances, customer advances and progress billings5,5159,4768,5918,7518,7242,673
Inventory5,5159,4768,5918,7518,7242,673
Prepaid expense3,6423,8303,8895,3225,8672,540
Other current assets256230739891236
Other undisclosed current assets5,9015,9637,28311,04614,1276,818
Total current assets:162,686143,580136,578132,510147,658156,817
Noncurrent Assets
Operating lease, right-of-use asset5,3736,1472,8283,7164,5795,417
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization187305388474515601
Intangible asset, including goodwill, after accumulated amortization41,39243,82746,26248,69751,13153,566
Intangible asset, excluding goodwill, after accumulated amortization41,39243,82746,26248,69751,13153,566
Prepaid expense2,6731,8301,6581,4911191,991
Restricted cash and investments    2,0912,0912,091
Deferred income tax assets3,8307,0757,0757,0757,075 
Other undisclosed noncurrent assets16198127127165238
Total noncurrent assets:53,61659,28258,33863,67165,67563,904
TOTAL ASSETS:216,302202,862194,916196,181213,333220,721
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities55,08743,50237,22132,89942,40758,171
Accounts payable5,0566,3865,4246,0265,5097,509
Accrued liabilities50,03137,11631,79726,87336,89850,662
Debt22,52333,71633,99745,32945,32945,329
Other liabilities142182223264  
Other undisclosed current liabilities3,5015,3287,6588,1718,3756,897
Total current liabilities:81,25382,72879,09986,66396,111110,397
Noncurrent Liabilities
Long-term debt and lease obligation   10,86910,64721,71932,746
Long-term debt, excluding current maturities   10,86910,64721,71932,746
Liabilities, other than long-term debt4,7094,866  1,7363,190
Accounts payable and accrued liabilities     121121
Other liabilities     121121
Operating lease, liability4,7094,866  1,4942,948
Other undisclosed noncurrent liabilities   2301,7631,6423,300
Total noncurrent liabilities:4,7094,86611,09912,41025,09739,236
Total liabilities:85,96287,59490,19899,073121,208149,633
Equity
Equity, attributable to parent130,340115,268104,71897,10892,12571,088
Common stock555555
Additional paid in capital1,414,0741,412,4571,410,7841,409,0261,407,0001,405,248
Accumulated other comprehensive income (loss)3619(14)(11)626
Accumulated deficit(1,283,775)(1,297,213)(1,306,057)(1,311,912)(1,314,886)(1,334,191)
Total equity:130,340115,268104,71897,10892,12571,088
TOTAL LIABILITIES AND EQUITY:216,302202,862194,916196,181213,333220,721

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues75,45354,47552,43646,00759,07780,542
Cost of revenue
(Cost of Product and Service Sold)		(23,127)(12,173)(12,301)(10,556)(13,921)(29,097)
Gross profit:52,32642,30240,13535,45145,15651,445
Operating expenses(35,220)(32,729)(33,499)(31,467)(31,791)(29,366)
Operating income (loss):17,1069,5736,6363,98413,36522,079
Nonoperating income (expense)1(330)(471)(717)(1,127)(1,471)
Investment income, nonoperating9771,0449561,1011,2261,282
Other nonoperating income143115410359268347
Interest and debt expense(1,119)(1,489)(1,837)(2,177)(2,621)(3,100)
Income (loss) from continuing operations before equity method investments, income taxes:15,9887,7544,3281,0909,61717,508
Other undisclosed income from continuing operations before income taxes1,1191,4891,8372,1772,6213,100
Income (loss) from continuing operations before income taxes:17,1079,2436,1653,26712,23820,608
Income tax expense (benefit)(3,669)(399)(310)(293)7,067(291)
Net income (loss) available to common stockholders, diluted:13,4388,8445,8552,97419,30520,317

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net income (loss):13,4388,8445,8552,97419,30520,317
Comprehensive income (loss):13,4388,8445,8552,97419,30520,317
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1733(3)(17)(20)58
Comprehensive income (loss), net of tax, attributable to parent:13,4558,8775,8522,95719,28520,375

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: